InCube Ventures is led by Mir Imran, a prolific medical innovator and company builder. Under Mir's leadership, InCube Ventures has access to ventures formed by InCube Labs - a multi-disciplinary research lab that has been a highly productive source of medical device companies. Mir and InCube Labs have formed 20 companies over the past 25 years, creating a series of multi-billion dollar markets along the way. In addition to Mir, the team consists of proven healthcare entrepreneurs, executives and investors.
- Mir Imran, Chairman & CEO
Mir Imran founded InCube Labs to focus on his passion: creating medical solutions that change the standard of care in critical healthcare markets. After attending medical school, Mir began his career as a healthcare entrepreneur in the late 1970's and has founded numerous game-changing companies since those early days. Over the decades, he has become one of the leading inventors and entrepreneurs in the field. Mir now holds more than 200 issued patents and is perhaps most well known for his pioneering contributions to the first FDA-approved Automatic Implantable Cardioverter Defibrillator. As an entrepreneur, Mir has founded more than 20 life sciences companies; 15 of his companies have seen "liquidity events" (IPO/Acquisition). Mir's expertise spans a wide range of clinical areas from interventional cardiology to chronic pain, obesity and CNS disorders. Mir actively collaborates with the nation's top universities on research and development including Stanford, Rutgers, Johns Hopkins, UTSW, etc. Mir also founded InCube Ventures, a life sciences venture fund, where he has led investments in a range of promising ventures. Mir sits on Boards of several life sciences companies. He holds an M.S. in bioengineering and a B.S. in electrical engineering from Rutgers. He also attended CMDNJ/Rutgers Medical School.
- Andrew Farquharson, Managing Director
Andrew is an investor and entrepreneur with two decades of experience building, restructuring and acquiring companies in life sciences. A founding member of InCube's venture fund, Andrew is also an advisor to InCube Labs, LLC, which develops breakthrough medical technologies under the leadership of Mir Imran.
Prior to joining InCube, Andrew served as a Partner in the Halo Funds, where he completed a Kauffman Fellowship and led investments in a portfolio of life science firms. These investments include Intrapace (obesity), Penumbra (ischemic stroke), Sonoma Orthopedic Products (bone repair), SwitchGear Genomics (gene regulation) & Spinal Modulation (pain management). Andrew has also been an active angel investor in a broader variety of ventures.
Earlier in his career, Andrew served as Executive Vice President of sales, marketing and research for Operon Technologies. During his tenure there, Andrew built a global sales force from scratch, grew revenues of synthetic DNA products to $40M in two years, and helped to negotiate a sale of the business to QIAGEN for $150M. He subsequently acquired a company in Japan for QIAGEN, and restructured it into the company's global operations. Prior to Operon, Andrew held several roles in research operations at Genentech, Inc., where he managed $200M of protein therapeutic production and optimized cell lines for expression. Andrew has also co-founded a gene design business in agricultural biotechnology (Glucazyme), launched a company in microfludics (Innovadyne), sat on a wide range of boards, and developed strategies for healthcare firms as a consultant with Deloitte & Touche.
Andrew holds a Masters of Business Administration from Harvard University and a Bachelor's from the University of California at Berkeley.
- Wayne Roe, Managing Director
Wayne pioneered the field of new product reimbursement planning and is widely recognized as America's foremost expert on third party payment and pharmacoeconomic strategy for new drugs, biologics and personalized medical therapies products.
Wayne was the founding officer and chairman of Covance Health Economics and Outcomes Services, Inc. from 1988 through 1999. Prior to that, he served as vice president for Economic and Health Policy for the Health Industry Manufacturers Association. He has been an advisor on health policy and medical innovation to the U.S. Congress, the Medicare Program and the Blue Cross Association. Wayne played a major role in developing and executing successful commercialization and reimbursement strategies for EPO, GCSF, Alfa Interferon, Ceredase, Enbrel, MRI imaging, laparoscopic surgical procedures, and scores of other blockbuster life sciences innovations.
Wayne has served on Boards of more than a dozen innovative life sciences companies over the last 20 years. He currently sits on the Boards of Directors of ISTA Pharmaceuticals, Celera Genomics, Hemaquest Inc., Fe2, Intrapace and Spinal Modulation. He is a strategic advisor to the Maryland Life Sciences Incubator, and serves on the executive committee of the Maryland Angels Investment Fund.
- Bill Ringo, Former Executive Pfizer and Lilly
Mr. Ringo served as the Senior Vice President Strategy and Business Development at Pfizer from 2008-2010. Mr. Ringo currently serves as a Senior Advisor to Barclays Capital and executive in residence at Sofinnova. In addition, Mr. Ringo serves as Chairman of the Board for Sangamo BioSciences, which is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification, and holds a Board seat for Onyx Pharmaceuticals, Inc., a biopharmaceutical company committed to improving the lives of people with cancer. Mr. Ringo also serves on the Board of Directors of BioCrossroads, a public-private collaboration of corporate, university, government and entrepreneurial leaders that supports Indiana's life sciences research and corporate strengths in life sciences while encouraging business development in the region.
Prior to joining Pfizer, Mr. Ringo served as an executive in residence at Warburg Pincus and Sofinnova Ventures. From 2004 to 2006, he was President and CEO of Abgenix, Inc., a biotechnology firm focused on developing human antibodies as agents to treat cancer and other serious diseases. At Abgenix, he led efforts to transform the organization into a more focused product company by strengthening the senior management team and enhancing an existing partnership with Amgen, which purchased Abgenix in 2006.
Mr. Ringo began his career at Eli Lilly & Company in 1973 and during his 28-year tenure there he held a number of senior positions, including Product Group President for Oncology and Critical Care, President of Internal Medicine Products, President of the Infectious Diseases Business Unit, and Vice President of Sales and Marketing for U.S. Pharmaceuticals. He retired from Lilly in 2001. Mr. Ringo holds a B.S. in Business Administration and an M.B.A. from the University of Dayton.
- Matt Harrison, Vice President, ICL TexasMatt is a Vice President and Entrepreneur In Residence for InCube Labs in San Antonio. He leads InCube’s clean energy initiatives and business development efforts in Texas. Matt is responsible for helping to establish InCube’s presence in Texas and brings more than 15 years of technology and entrepreneurial experience to InCube. He holds a Bachelor of Science degree in electrical engineering from Texas A&M University.Matt is also a venture partner with InCube Ventures, a leading medical device venture capital firm, with offices in California and Texas.Prior to joining InCube, Matt was the General Manager of Texas Instruments' Medical Business Unit, where he was responsible for overall direction, growth, strategy, promotion, and execution of the business. Matt began his career with Texas Instruments in the mid-90s and held many roles and management positions. He led the creation of two internal business units for TI that contribute more than $50M in revenue, one focused in optical networking and the other in digital power.In 2003, Matt left TI and was a co-founder in Commoca, Incorporated (an IP phone communications company) where he served as COO and member of the Board of Directors. In August 2006, Matt was recruited back to TI to lead the company’s new medical initiative.Matt volunteers his time as a board member for multiple non-profit organizations.